# A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies

> **NCT02520427** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 95 (actual)

## Conditions studied

- Relapsed/Refractory AML
- Minimal Residual Disease Positive AML
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** AMG 330

## Key facts

- **NCT ID:** NCT02520427
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08-31
- **Primary completion:** 2022-01-09
- **Final completion:** 2022-01-09
- **Target enrollment:** 95 (ACTUAL)
- **Why stopped:** Amgen strategic business decision to cancel following portfolio review, re-prioritization.
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02520427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02520427, "A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02520427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*